CORDIS
EU research results

CORDIS

English EN

Next generation eco-friendly, microbiome preserving and reduced resistance therapeutics

Project information

Grant agreement ID: 862028

Status

Ongoing project

  • Start date

    1 July 2019

  • End date

    31 December 2020

Funded under:

H2020-EU.1.1.

Hosted by:

WEIZMANN INSTITUTE OF SCIENCE

Israel

Project description

English EN

Highly selective antibiotics may fight highly resistant human pathogens

Antibiotics (literally 'against life') kill bacteria. As our bodies are host to many 'good' bacteria, selective antibiotics are needed. Ribosomes are the site of protein synthesis and the target of novel therapeutics under development by NEXTER. The key is in targeting certain portions of ribosomes that are specific to certain species of bacteria. Using this strategy, scientists have stopped the growth of a multi-drug resistant strain of Staphylococcus aureus (S. aureus), an important human pathogen causing infection in both clinical and community settings. Further, these synthetic therapeutics are degradable meaning they will decrease environmental contamination, further reducing the development of resistant strains. The team is now targeting other pathogens and plans to take the pioneering technology to market soon.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Host institution

WEIZMANN INSTITUTE OF SCIENCE

Address

Herzl Street 234
7610001 Rehovot

Israel

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 150 000

Beneficiaries (1)

WEIZMANN INSTITUTE OF SCIENCE

Israel

EU Contribution

€ 150 000

Project information

Grant agreement ID: 862028

Status

Ongoing project

  • Start date

    1 July 2019

  • End date

    31 December 2020

Funded under:

H2020-EU.1.1.

Hosted by:

WEIZMANN INSTITUTE OF SCIENCE

Israel